Gyre Therapeutics, Inc.
GYRE
$6.68
$0.142.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 121.29M | 121.92M | 128.06M | 118.74M | 113.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 121.29M | 121.92M | 128.06M | 118.74M | 113.67M |
| Cost of Revenue | 6.81M | 5.75M | 5.42M | 4.85M | 4.18M |
| Gross Profit | 114.49M | 116.17M | 122.65M | 113.89M | 109.49M |
| SG&A Expenses | 96.10M | 96.95M | 91.68M | 83.48M | 81.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.70M | 129.71M | 120.72M | 110.85M | 108.47M |
| Operating Income | -19.41M | -7.78M | 7.35M | 7.89M | 5.20M |
| Income Before Tax | -24.90M | -12.04M | 11.83M | 12.67M | 8.97M |
| Income Tax Expenses | 3.38M | 4.20M | 4.56M | 3.46M | 2.84M |
| Earnings from Continuing Operations | -28.28 | -16.25 | 7.27 | 9.21 | 6.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.26M | 8.43M | -39.00K | -350.00K | 244.00K |
| Net Income | -19.02M | -7.81M | 7.23M | 8.86M | 6.37M |
| EBIT | -19.41M | -7.78M | 7.35M | 7.89M | 5.20M |
| EBITDA | -15.91M | -4.76M | 10.24M | 10.58M | 7.69M |
| EPS Basic | -0.24 | -0.15 | 0.02 | 0.04 | 0.01 |
| Normalized Basic EPS | -0.02 | 0.05 | 0.08 | 0.09 | 0.07 |
| EPS Diluted | -0.25 | -0.16 | -0.01 | 0.01 | -0.02 |
| Normalized Diluted EPS | -0.03 | 0.05 | 0.07 | 0.08 | 0.07 |
| Average Basic Shares Outstanding | 374.01M | 362.49M | 356.60M | 351.39M | 346.19M |
| Average Diluted Shares Outstanding | 387.13M | 375.70M | 369.99M | 364.78M | 363.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |